Vienna - Delayed Quote EUR

Sanofi (SANO.VI)

Compare
96.19
-0.51
(-0.53%)
At close: January 10 at 3:30:38 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
48,856,000.00
46,444,000.00
45,389,000.00
39,175,000.00
37,369,000.00
Cost of Revenue
14,982,000.00
14,236,000.00
13,695,000.00
12,255,000.00
12,159,000.00
Gross Profit
33,874,000.00
32,208,000.00
31,694,000.00
26,920,000.00
25,210,000.00
Operating Expense
23,319,000.00
21,816,000.00
19,813,000.00
17,773,000.00
17,320,000.00
Operating Income
10,555,000.00
10,392,000.00
11,881,000.00
9,147,000.00
7,890,000.00
Net Non Operating Interest Income Expense
-817,000.00
-639,000.00
-288,000.00
-370,000.00
-335,000.00
Other Income Expense
-3,617,000.00
-2,600,000.00
-1,171,000.00
-979,000.00
6,223,000.00
Pretax Income
6,121,000.00
7,153,000.00
10,422,000.00
7,798,000.00
13,778,000.00
Tax Provision
1,509,000.00
1,602,000.00
2,006,000.00
1,558,000.00
1,807,000.00
Earnings from Equity Interest Net of Tax
-63,000.00
-115,000.00
68,000.00
39,000.00
359,000.00
Net Income Common Stockholders
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Diluted NI Available to Com Stockholders
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Basic EPS
3.60
4.31
6.69
4.97
9.81
Diluted EPS
3.59
4.30
6.66
4.95
9.76
Basic Average Shares
1,251,400.00
1,251,700.00
1,251,900.00
1,252,500.00
1,253,600.00
Diluted Average Shares
1,253,580.72
1,256,400.00
1,256,900.00
1,257,900.00
1,260,100.00
Total Operating Income as Reported
7,021,000.00
7,875,000.00
10,656,000.00
8,126,000.00
14,113,000.00
Total Expenses
38,301,000.00
36,052,000.00
33,508,000.00
30,028,000.00
29,479,000.00
Net Income from Continuing & Discontinued Operation
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Normalized Income
7,231,306.98
7,417,600.00
9,317,168.00
7,006,400.87
7,005,316.81
Interest Income
531,000.00
546,000.00
173,000.00
3,000.00
103,000.00
Interest Expense
822,000.00
659,000.00
461,000.00
389,000.00
434,000.00
Net Interest Income
-817,000.00
-639,000.00
-288,000.00
-370,000.00
-335,000.00
EBIT
6,943,000.00
7,812,000.00
10,883,000.00
8,187,000.00
14,212,000.00
EBITDA
9,058,000.00
12,604,000.00
14,303,000.00
11,538,000.00
17,883,000.00
Reconciled Cost of Revenue
14,982,000.00
11,616,000.00
12,328,000.00
10,484,000.00
10,169,000.00
Reconciled Depreciation
2,115,000.00
4,792,000.00
3,420,000.00
3,351,000.00
3,671,000.00
Net Income from Continuing Operation Net Minority Interest
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Total Unusual Items Excluding Goodwill
-3,617,000.00
-2,600,000.00
-1,171,000.00
-979,000.00
6,087,000.00
Total Unusual Items
-3,617,000.00
-2,600,000.00
-1,171,000.00
-979,000.00
6,087,000.00
Normalized EBITDA
12,675,000.00
15,204,000.00
15,474,000.00
12,517,000.00
11,796,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-891,693.02
-582,400.00
-224,832.00
-195,599.13
798,316.81
12/31/2020 - 10/4/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4AB.F AbbVie Inc.
169.50
-2.47%
 
NOV.DE Novo Nordisk A/S
84.60
-0.31%
 
BAYN.DE Bayer Aktiengesellschaft
19.98
+1.13%
 
OGN Organon & Co.
15.85
-0.94%
 
GSK GSK plc
33.09
-1.96%
 
MRK Merck & Co., Inc.
99.25
-0.60%
 
ABBV AbbVie Inc.
175.17
-1.87%
 
NVO Novo Nordisk A/S
86.26
+0.72%
 
PFE Pfizer Inc.
26.72
-0.52%
 
JNJ Johnson & Johnson
142.06
-0.15%